Compugen announced positive results for its trial of CGEN-15022, a membrane protein that was discovered by the company, as a treatment of multiple cancers such as liver, colorectal, lung and ovarian cancers. According to the company, the results indicate the potential of the protein as a compelling drug target for treatment of these cancers through monoclonal antibody (mAb) therapy. Compugen is a product discovery company focused on therapeutic proteins and monoclonal antibodies, based in Tel Aviv, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments